Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2026; 2. Consider the Limited Review Reports'' of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Half-Year ....

—— & SENNEX Ref: GLL/SE /2026-27/Nov - Date: 03/11/2026 To To The General Manager, The Listing Manager, Corporate Relations Department, The Ahmedabad Stock Exchange Limited BSE Limited A-2, Kamdhenu Complex, Phiroze Jeejeebhoy Towers, Opp. Sahajanand College, Dalal Street, Mumbai - 400001. 120 Feet Ring Road, Panjara Pol, Ambawadi, Maharashtra State, India. Ahmedabad - 380015. Script Code: 531739 Gujarat State, India. Script Code: The Calcutta Stock Exchange Limited, #7, Lyons Range, Murgighata, Dalhousie, Kolkata - 700001, West Bengal State, India. Script Code: 26178 Dear Sir/Madam, Sub: Intimation of Board Meeting to be held on Saturday, November 14, 2026 of Gennex Laboratories Limited Ref: Regulation 29(1)}(a), 33 and 47 of SEBI (LODR) Regulations, 2015 With reference to the above captioned subject matter, we hereby inform you that the Meeting of Board of Directors of the Company will be held on Saturday, November 14, 2026 at 04:00 PM at the Corporate Office of the Company, inter-alia, consider the following matters, among other items of agenda: 1. Consider and adopt the Unaudited Financial Statements (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2026; 2. Consider the Limited Review Reports’ of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Half-Year ended September 30, 2026; 3. Other Business items. Further, in continuation to earlier disclosure dated September 22, 2026, regarding the closure of trading window w.e.f. October 01, 2026 in pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, Trading Window for dealing in the securities of the Company shall open after 48 hours of declaration of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026 for all designated persons, their immediate relatives and all connected persons covered under the aforesaid code. This intimation is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same. Thanking you, Yours faithfully For Gennex Laboratories Limited DINESH KR fale KEJRIWAL pas 2026.11.03 14:78:18 Dinesh Kumar Kejriwal Company Secretary & Compliance Officer Membership #A19293 Gennex Laboratories Limited Office: ‘Akash Ganga’ 4" Floor, Plot NO.144, Srinagar colony, Hyderabad-500073, T.S. India | Phone: +91-40-67334400 (30 Lines), Fax: +91-40-67334433 Factory: Sy.No.133, IDA Bollaram, Jinnaram Mandal, Sangareddy Dist — 502325, Telangana, India | Tel: +91-08458 279406, Telefax: +91-08454 279516 Info(@gennexlab.com, www.gennexlab.com i CIN: L24230TG1990PLC011168